3-hydroxy-4-methoxybenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-hydroxy-4-methoxybenzamide
• 化学式: C₈H₉NO₃
• 分子量: 167.164
• InChiKey: DXKBWXYICSWPJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-羟基-4-甲氧基苯甲醇 在 iron(III) chloride 、 2,2,6,6-四甲基哌啶氧化物 、 盐酸羟胺 、 碘 、 potassium carbonate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 15.0h， 以78%的产率得到3-hydroxy-4-methoxybenzamide
  参考文献：
  名称：

  I2-TEMPO as an efficient oxidizing agent for the one-pot conversion of alcohol to amide using FeCl3 as the catalyst

  摘要：

  A high yield one-pot method for the synthesis of amides from alcohols is described. The aldehyde was generated in situ using iodine-TEMPO as oxidizing agent followed by intermediate oxime formation through reaction with NH2OH center dot HCl and finally rearrangement of oxime catalyzed by FeCl3. (C) 2012 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.catcom.2012.04.027

文献信息

• Antidiabetic agents
  申请人：Pfizer Products Inc.

  公开号：EP1340500A1

  公开（公告）日：2003-09-03

  A compound of the formula wherein n, m, Z, R1, R5, R8, R9, R10 and R11 are as defined above, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia.

  一种具有上述定义的化合物的分子式，用于治疗糖尿病、胰岛素抵抗、糖尿病神经病变、糖尿病肾病、糖尿病视网膜病变、白内障、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和组织缺血，特别是心肌缺血。
• Benzimidazoles
  申请人：Edwards L. Michael

  公开号：US20060014756A1

  公开（公告）日：2006-01-19

  The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

  本发明涉及一般式（Ix）的生理活性化合物及含有这种化合物的组合物，以及它们的前药、药学上可接受的盐和溶剂化物，还涉及在式（Ix）范围内的新化合物和它们的制备方法。这种化合物和组合物具有有价值的药物性质，特别是抑制激酶的能力。
• Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
  申请人：Garofalo W. Albert

  公开号：US20050032868A1

  公开（公告）日：2005-02-10

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明涉及一种用于治疗哺乳动物中由于缓激肽B1受体介导的疾病或缓解与疾病状态相关的不良症状的缓激肽B1受体拮抗剂化合物。其中某些化合物表现出增强的效力，并且预计还会表现出增强的作用持续时间。
• 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
  申请人：Garofalo W. Albert

  公开号：US20070123531A1

  公开（公告）日：2007-05-31

  Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明涉及一种可以用于治疗哺乳动物中由于Bradykinin B1受体介导的疾病或缓解与疾病状态相关的不良症状的化合物，这些化合物是Bradykinin B1受体拮抗剂。其中某些化合物表现出增强的效力，并且预计还将表现出增加的作用持续时间。
• Theramutein modulators
  申请人：Housey, Gerard M.

  公开号：EP2447252A2

  公开（公告）日：2012-05-02

  This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

  本发明涉及作为内源蛋白质变异形式的抑制剂或激活剂的制剂，以及鉴定这种变异体的新方法。特别令人感兴趣的是由基因突变编码的内源蛋白质变体的抑制剂和激活剂，这种变体往往是在接触已知是相应的未突变内源蛋白质的抑制剂或激活剂的化学制剂后产生的，或至少是在接触这种化学制剂后首次被确定为产生的。